

ASAP BioPharma Conference 2018 Agenda



Find the most up-to-date details at
www.asapbiopharma.org
**Sessions, times, and speakers are subject to change.*

September 24-26, 2018
Boston, Massachusetts

ASAP BioPharma Conference Agenda

As of 6.18.18. Details subject to change. Updates at www.asapbiopharma.org.

Day 1 | September 24, 2018 | Pre-Conference Workshops

| Time | Session # | Session Name | Speaker |
|-------------------|-----------|--|---|
| 8:00am - 5:30pm | | Registration | |
| 9:30am - 3:30pm | | Pre-Conference Workshops | |
| | 101 | CA-AM (Certificate of Achievement - Alliance Management) Certification Exam Prep Workshop | <ul style="list-style-type: none">• Lynda McDermott, CA-AM President Equipro |
| | 102 | Alliance Management 201: The Value of Alliance Management | <ul style="list-style-type: none">• David Thompson, CA-AM Chief Alliance Officer Eli Lilly and Company• Gary Butkus, CA-AM Director of Alliance Management Eli Lilly and Company |
| 12:00pm - 12:45pm | | Workshop Lunch | |
| 11:30am - 12:30pm | | Leadership Lunch ~ Invitation Only | |
| 12:30pm - 3:30pm | | Leadership Forum ~ Invitation Only | |
| | | Pre-Conf. Sessions | |
| 4:00pm - 5:00pm | | Next Gen Alliance Management: Moving your Organization to Ecosystem Performance Excellence | <ul style="list-style-type: none">• Lynda McDermott, CA-AM President Equipro |
| 5:30pm - 6:30pm | | Welcome Reception | |

Day 2 | September 25, 2018 | Conference

| Time | Session # | Session Name | Speaker |
|-------------------|-----------|--|--|
| 7:00am - 8:15am | | Networking Breakfast | |
| 8:30am - 8:45am | | Opening Remarks | |
| 8:45am - 9:30am | 201 | A CEO Fireside Chat: Alliance Management's Value in the C-Suite | ★ Corey McCann, MD, PhD Founder and Chief Executive Officer Pear Therapeutics |
| 9:40am - 10:30am | 202 | Plenary Panel Title TBA | Moderator <ul style="list-style-type: none"> • Andy Eibling, CSAP Senior Partner Forty86 Consulting Group Speakers <ul style="list-style-type: none"> • Nick Dunscombe Vice President, Business & Commercial Development Astellas Pharma Europe • Mojgan Hossein-Nia, PhD Vice President, Head R&D Partnership Office Takeda • Steve Twait, CSAP Vice President, Alliance and Integration Management AstraZeneca • Lucinda Warren Vice President Business Development Johnson & Johnson Innovation / Janssen Business Development |
| 10:30am - 11:00am | | Networking Break | |
| 11:00am - 11:50am | 301 | Non-traditional Partnerships: The Changing BioPharma Alliance Landscape and the Implications for the Alliance Professional and Alliance Management Community | <ul style="list-style-type: none"> • Stuart Kliman, CA-AM Partner Vantage Partners • Ben Siddall Partner Vantage Partners |
| 11:00am - 11:50am | 401 | Let's Make a Deal: Driving Better Contracts to Win in Clinical Genomics | <ul style="list-style-type: none"> • Katherine Ellison, CA-AM Associate Director, Alliances Illumina, Inc. • TBD Illumina, Inc. |
| 12:00pm - 1:00pm | | Networking Lunch | |
| 1:10pm - 2:00pm | 302 | Tech Start-Up Meets Pharma: Building a 'New Normal' | <ul style="list-style-type: none"> • Craig McDonald Director, Alliance Management Otsuka America Pharmaceutical, Inc. • Tom Richards Director, Alliance Management Otsuka America Pharmaceutical, Inc. |
| 1:10pm - 2:00pm | 402 | When 1+1 = More than 2: Harnessing the Power of the Technical Expert | <ul style="list-style-type: none"> • Soo Bang, CA-AM Vice President, Business Strategy, Intergration & Planning Celgene • Jason M. Urban, PhD Senior Director, Business Strategy & Process Excellence Celgene |

Day 2 | September 25, 2018 | Conference *(continued)*

| Time | Session # | Session Name | Speaker |
|-----------------|-----------|--|--|
| 2:10pm - 3:00pm | 303 | To Tango or Slow Dance: The Question in Companion Diagnostic Development | <ul style="list-style-type: none"> Ellen Locker Executive Director, Alliance Management Merck & Co. Trevor Page Chief Business Officer Agilent Technologies |
| | 403 | Essential Role of the Alliance Manager in Deal Negotiation | <ul style="list-style-type: none"> Stacie Wild Business Development Director, Alliance Management Amgen Angela Bylancik, CA-AM Executive Director BD&L, Global Alliance Management Novartis |
| 3:00pm - 3:30pm | | Networking Break | |
| 3:30pm - 4:20pm | 203 | Speak My Language: How to Have a High Impact Conversation with the C-suite | <p>Moderator</p> <ul style="list-style-type: none"> Christine A. Carberry, CSAP Chief Operating Officer Keryx Biopharmaceuticals <p>Speakers</p> <ul style="list-style-type: none"> James C. Mullen Chairman of the Board of Directors Editas Medicine, Inc. Samantha Singer Chief Operating Officer Broad Institute Alex Waldron Chief Commercial Officer Pear Therapeutics |
| 4:30pm - 5:20pm | 204 | Roundtables | |
| 5:30pm - 6:30pm | | Networking Reception | |

Day 3 | September 26, 2018 | Conference

| Time | Session # | Session Name | Speaker |
|------------------|-----------|---|---|
| 7:00am - 8:30am | | Networking Breakfast | |
| 8:30am - 9:15am | 205 | Alliances as Enablers of Scientific Innovation | <ul style="list-style-type: none"> ★ Jeff Karp, PhD Co-founder of Six Companies Brigham and Women's Hospital, Harvard Medical School |
| 9:25am - 10:15am | 304 | Taming the Octopus: Managing the Web of Clinical Collaborations | <ul style="list-style-type: none"> Jan Twombly, CSAP President The Rhythm of Business Judy Baselice Director, Alliance Management Pfizer Inc. Ellen Locker Executive Director, Alliance Management Merck & Co. |
| | 404 | Why Alliance Management Is So Critical to Divestments | <ul style="list-style-type: none"> Emma Barton, PhD Director, Alliance and Integration Management (AIM) AstraZeneca Elena Cavalli, CSAP Director, Alliance Management and Corporate Development Astellas Pharma Europe |

Day 3 | September 26, 2018 | Conference *(continued)*

| Time | Session # | Session Name | Speaker |
|-------------------|-----------|--|--|
| 10:15am - 10:40am | | Networking Break | |
| 10:40am - 12:10pm | 501 | Harnessing Alliance Inflection Points (and Associated Conflict) | <ul style="list-style-type: none"> • Lena Frank, CSAP Executive Director of Alliance and Program Management Eisai Inc. • Kevin Little, CSAP, PhD Chief Scientific Officer 3D Signatures, Inc. • David Thompson, CA-AM Chief Alliance Officer Eli Lilly and Company |
| | 502 | Building Alliance Lifecycle Value: Overlapping Business Development and Alliance Management Best Practices | <ul style="list-style-type: none"> • Anthony Hoerning, CSAP Founder Strategic Transactions Advisory AG |
| 12:20pm - 1:20pm | | Lunch | |
| 1:30pm - 2:20pm | 305 | Innovating an Alliance: Opportunities and Complexities in Facilitating a Restructure | <ul style="list-style-type: none"> • Cathy Connelly, CA-AM Vice President & Head of Alliance Management Sanofi Genzyme • Vin Sharma Senior Director & Head, Alliance Management Alnylam Pharmaceuticals |
| | 405 | Due Diligence: Building Value into Strategic Partnerships | <ul style="list-style-type: none"> • Brent Harvey, CA-AM Director, Alliance Management Eli Lilly and Company • Kristi Huntington, CA-AM Director, Pharmaceutical Project Management - Neurodegeneration Eli Lilly and Company |
| 2:20pm - 2:40pm | | Networking Break | |
| 2:40pm - 3:30pm | 306 | Grappling with 'Wicked Problems' in Alliance Management | <ul style="list-style-type: none"> • Jeremy Ahouse, CSAP, PhD Vice President Alliances Merus |
| | 406 | Panel Discussion Title TBA | <p>Moderator</p> <ul style="list-style-type: none"> • Brenda Schultz, CSAP President & Principal Advisor Strategic Partners, LLC <p>Panelists</p> <ul style="list-style-type: none"> • Frederic Bonfils, CSAP VP Corporate Alliance Management Pierre Fabre • Lynnelle Pittet, CA-AM, PhD Director, Alliance and Program Management WAVE Lifesciences • Petra Sansom, CA-AM, PhD Senior Director, Alliance Management Vertex |
| 3:40pm - 4:00pm | | Wrap-up | |